pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › VRTX

VRTX PDUFA Date: Povetacicept (ALPN-303)

FDA decision (PDUFA) target 2026-11-30 · Vertex Pharmaceuticals Incorporated · Lupus nephritis, IgA nephropathy

VRTX run-up into the PDUFA (last ~120 days)

$499.17$423.24
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-11-30
Drug / candidatePovetacicept (ALPN-303)
IndicationLupus nephritis, IgA nephropathy
CompanyVertex Pharmaceuticals Incorporated
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNCT06564142 · nan

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the VRTX PDUFA date?
The FDA PDUFA target date for VRTX (Vertex Pharmaceuticals Incorporated) is 2026-11-30 for Povetacicept (ALPN-303). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is VRTX's drug Povetacicept (ALPN-303)?
Povetacicept (ALPN-303) is Vertex Pharmaceuticals Incorporated's candidate under FDA review for Lupus nephritis, IgA nephropathy.
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.